SCHEMBL4870666

SCHEMBL4870666

CCN(CCNC(=O)N1CCCCc2ccc(F)cc21)c1cccc(C)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 6/20 0.47
ALDH1A1 P00352 4/20 0.47
MAPT P10636 3/20 0.47
GAA P10253 3/20 0.47
HPGD P15428 2/20 0.47
HTT P42858 2/20 0.47
KDM4E B2RXH2 1/20 0.47
KMT2A Q03164 2/20 0.46
LMNA P02545 3/20 0.45
TSHR P16473 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
NPSR1 Q6W5P4 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
AVPR2 P30518 1/20 0.42
TP53 P04637 2/20 0.41
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4868949 0.90 LMNA (0.53) GFERALDH1A1MAPTGAAHPGD
SCHEMBL4872578 0.86 AVPR2 (0.52) GFERMAPTKMT2ALMNANPSR1
SCHEMBL4870765 0.82 AVPR2 (0.54) GFERMAPTKDM4EKMT2ALMNA
SCHEMBL4868380 0.82 LMNA (0.54) GFERALDH1A1MAPTGAAHPGD
SCHEMBL4870682 0.81 AVPR2 (0.51) GFERALDH1A1MAPTGAAHPGD
SCHEMBL4865179 0.80 GFER (0.53) GFERMAPTKMT2ALMNACYP1A2
SCHEMBL4862339 0.79 GFER (0.49) GFERALDH1A1MAPTGAAHPGD
SCHEMBL4870764 0.77 LMNA (0.52) GFERALDH1A1MAPTGAAHPGD
SCHEMBL4869509 0.77 AVPR2 (0.52) MAPTKDM4EKMT2ALMNANPSR1
SCHEMBL4870670 0.74 AVPR2 (0.49) MAPTKMT2ALMNAAVPR2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US disclosed
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 US disclosed
EP-1475368-A1 N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient CNR1, CNR2, NPSR1 GFER 781/4885ALDH1A1 3990/4885MAPT 3398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.